BlackRock Virginia Municipal Bond Trust (BHV)
Market Closed
2 Jul, 20:00
NYSE NYSE Primary $
12. 70
-0.02
-0.1572%
Pre Market
$
+0.1 +0.7874% 12. 80
- Market Cap
- Div Yield
1,949 Volume
$ 12.72
Previous Close Investors:
Want to track BHV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-1300 in Graves' Disease and BHV-1400 in IgA Nephropathy in mid-2026, targeting large unmet markets. Phase 1b data show over 80% reduction in pathogenic TSHR-IgG1 for BHV-1300 and over 60% Gd-IgA1 reduction for BHV-1400, with safety advantages over competitors.
Seekingalpha | 2 weeks ago
